| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Journal of General Virology, Vol 79, 347-352, Copyright © 1998 by Society for General Microbiology
ARTICLES |
I Drexler, K Heller, B Wahren, V Erfle and G Sutter
Institut fur Molekulare Virologie, GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH, Munchen-Neuherberg, Germany.
Although desirable for safety reasons, the host range restrictions of modified vaccinia virus Ankara (MVA) make it less applicable for general use. Propagation in primary chicken embryo fibroblasts (CEF) requires particular cell culture experience and has no pre-established record of tissue culture reproducibility. We investigated a variety of established cell lines for productive virus growth and recombinant gene expression. Baby hamster kidney cells (BHK), a well-characterized, easily maintained cell line, supported MVA growth and as proficient expression of the E. coli lacZ reporter gene as the highly efficient CEF, whereas other cell lines were non-permissive or allowed only very limited MVA replication. Importantly, no virus production occurred in patient-derived infected primary human cells. These results emphasize the safety and now improved accessibility of MVA for the development of expression vectors and live recombinant vaccines.
This article has been cited by other articles:
|
|
 |
|
  P. L. Earl, J. L. Americo, L. S. Wyatt, O. Espenshade, J. Bassler, K. Gong, S. Lin, E. Peters, L. Rhodes Jr, Y. E. Spano, et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus PNAS, August 5, 2008; 105(31): 10889 - 10894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Day, I. A. Ramshaw, A. J. Ramsay, and C. Ranasinghe Differential Effects of the Type I Interferons {alpha}4, {beta}, and {epsilon} on Antiviral Activity and Vaccine Efficacy J. Immunol., June 1, 2008; 180(11): 7158 - 7166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Meisinger-Henschel, M. Schmidt, S. Lukassen, B. Linke, L. Krause, S. Konietzny, A. Goesmann, P. Howley, P. Chaplin, M. Suter, et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara J. Gen. Virol., December 1, 2007; 88(12): 3249 - 3259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Waibler, M. Anzaghe, H. Ludwig, S. Akira, S. Weiss, G. Sutter, and U. Kalinke Modified Vaccinia Virus Ankara Induces Toll-Like Receptor-Independent Type I Interferon Responses J. Virol., November 15, 2007; 81(22): 12102 - 12110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chavan, K. A. Marfatia, I. C. An, D. A. Garber, and M. B. Feinberg Expression of CCL20 and Granulocyte-Macrophage Colony-Stimulating Factor, but Not Flt3-L, from Modified Vaccinia Virus Ankara Enhances Antiviral Cellular and Humoral Immune Responses. J. Virol., August 1, 2006; 80(15): 7676 - 7687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Najera, C. E. Gomez, E. Domingo-Gil, M. M. Gherardi, and M. Esteban Cellular and Biochemical Differences between Two Attenuated Poxvirus Vaccine Candidates (MVA and NYVAC) and Role of the C7L Gene. J. Virol., June 1, 2006; 80(12): 6033 - 6047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ludwig, Y. Suezer, Z. Waibler, U. Kalinke, B. S. Schnierle, and G. Sutter Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus Ankara. J. Gen. Virol., May 1, 2006; 87(Pt 5): 1145 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Valderrama, J. V. Cordeiro, S. Schleich, F. Frischknecht, and M. Way Vaccinia Virus-Induced Cell Motility Requires F11L-Mediated Inhibition of RhoA Signaling Science, January 20, 2006; 311(5759): 377 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Okeke, O. Nilssen, and T. Traavik Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines J. Gen. Virol., January 1, 2006; 87(1): 21 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Li, N. Chen, R. L. Roper, Z. Feng, A. Hunter, M. Danila, E. J. Lefkowitz, R. M. L. Buller, and C. Upton Complete coding sequences of the rabbitpox virus genome J. Gen. Virol., November 1, 2005; 86(11): 2969 - 2977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Staib, S. Kisling, V. Erfle, and G. Sutter Inactivation of the viral interleukin 1{beta} receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara J. Gen. Virol., July 1, 2005; 86(7): 1997 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Stittelaar, G. van Amerongen, I. Kondova, T. Kuiken, R. F. van Lavieren, F. H. M. Pistoor, H. G. M. Niesters, G. van Doornum, B. A. M. van der Zeijst, L. Mateo, et al. Modified Vaccinia Virus Ankara Protects Macaques against Respiratory Challenge with Monkeypox Virus J. Virol., June 15, 2005; 79(12): 7845 - 7851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, L. Zhang, C. Qin, L. Ba, C. E. Yi, F. Zhang, Q. Wei, T. He, W. Yu, J. Yu, et al. Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region J. Virol., March 1, 2005; 79(5): 2678 - 2688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ludwig, J. Mages, C. Staib, M. H. Lehmann, R. Lang, and G. Sutter Role of Viral Factor E3L in Modified Vaccinia Virus Ankara Infection of Human HeLa Cells: Regulation of the Virus Life Cycle and Identification of Differentially Expressed Host Genes J. Virol., February 15, 2005; 79(4): 2584 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Drillien, D. Spehner, and D. Hanau Modified vaccinia virus Ankara induces moderate activation of human dendritic cells J. Gen. Virol., August 1, 2004; 85(8): 2167 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Makitalo, P. Lundholm, J. Hinkula, C. Nilsson, K. Karlen, A. Morner, G. Sutter, V. Erfle, J. L. Heeney, B. Wahren, et al. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen J. Gen. Virol., August 1, 2004; 85(8): 2407 - 2419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Guerra, L. A. Lopez-Fernandez, R. Conde, A. Pascual-Montano, K. Harshman, and M. Esteban Microarray Analysis Reveals Characteristic Changes of Host Cell Gene Expression in Response to Attenuated Modified Vaccinia Virus Ankara Infection of Human HeLa Cells J. Virol., June 1, 2004; 78(11): 5820 - 5834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bisht, A. Roberts, L. Vogel, A. Bukreyev, P. L. Collins, B. R. Murphy, K. Subbarao, and B. Moss Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice PNAS, April 27, 2004; 101(17): 6641 - 6646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Wyatt, P. L. Earl, L. A. Eller, and B. Moss Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge PNAS, March 30, 2004; 101(13): 4590 - 4595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cosma, S. Buhler, R. Nagaraj, C. Staib, A.-L. Hammarin, B. Wahren, F. D. Goebel, V. Erfle, and G. Sutter Neutralization Assay Using a Modified Vaccinia Virus Ankara Vector Expressing the Green Fluorescent Protein Is a High-Throughput Method To Monitor the Humoral Immune Response against Vaccinia Virus Clin. Vaccine Immunol., March 1, 2004; 11(2): 406 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Meiser, C. Sancho, and J. Krijnse Locker Plasma Membrane Budding as an Alternative Release Mechanism of the Extracellular Enveloped Form of Vaccinia Virus from HeLa Cells J. Virol., September 15, 2003; 77(18): 9931 - 9942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fischer, O. Planz, L. Stitz, and H.-J. Rziha Novel Recombinant Parapoxvirus Vectors Induce Protective Humoral and Cellular Immunity against Lethal Herpesvirus Challenge Infection in Mice J. Virol., September 1, 2003; 77(17): 9312 - 9323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hornemann, O. Harlin, C. Staib, S. Kisling, V. Erfle, B. Kaspers, G. Hacker, and G. Sutter Replication of Modified Vaccinia Virus Ankara in Primary Chicken Embryo Fibroblasts Requires Expression of the Interferon Resistance Gene E3L J. Virol., August 1, 2003; 77(15): 8394 - 8407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, M. Messerle, R. Sapinoro, K. Santos, P. K. Hocknell, X. Jin, and S. Dewhurst Murine Cytomegalovirus Abortively Infects Human Dendritic Cells, Leading to Expression and Presentation of Virally Vectored Genes J. Virol., July 1, 2003; 77(13): 7182 - 7192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Meiser, D. Boulanger, G. Sutter, and J. Krijnse Locker Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release J. Gen. Virol., June 1, 2003; 84(6): 1383 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. U. Vogel, H. Horton, D. H. Fuller, D. K. Carter, K. Vielhuber, D. H. O'Connor, T. Shipley, J. Fuller, G. Sutter, V. Erfle, et al. Differences Between T Cell Epitopes Recognized After Immunization and After Infection J. Immunol., October 15, 2002; 169(8): 4511 - 4521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. U. Vogel, T. C. Friedrich, D. H. O'Connor, W. Rehrauer, E. J. Dodds, H. Hickman, W. Hildebrand, J. Sidney, A. Sette, A. Hughes, et al. Escape in One of Two Cytotoxic T-Lymphocyte Epitopes Bound by a High-Frequency Major Histocompatibility Complex Class I Molecule, Mamu-A*02: a Paradigm for Virus Evolution and Persistence? J. Virol., October 11, 2002; 76(22): 11623 - 11636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Sancho, S. Schleich, G. Griffiths, and J. Krijnse-Locker The Block in Assembly of Modified Vaccinia Virus Ankara in HeLa Cells Reveals New Insights into Vaccinia Virus Morphogenesis J. Virol., July 17, 2002; 76(16): 8318 - 8334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Ober, P. Bruhl, M. Schmidt, V. Wieser, W. Gritschenberger, S. Coulibaly, H. Savidis-Dacho, M. Gerencer, and F. G. Falkner Immunogenicity and Safety of Defective Vaccinia Virus Lister: Comparison with Modified Vaccinia Virus Ankara J. Virol., June 27, 2002; 76(15): 7713 - 7723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Durbin, M. H. Skiadopoulos, J. M. McAuliffe, J. M. Riggs, S. R. Surman, P. L. Collins, and B. R. Murphy Human Parainfluenza Virus Type 3 (PIV3) Expressing the Hemagglutinin Protein of Measles Virus Provides a Potential Method for Immunization against Measles Virus and PIV3 in Early Infancy J. Virol., August 1, 2000; 74(15): 6821 - 6831. [Abstract] [Full Text]
|
|
|
|
|
|
J. C. Ramírez, M. M. Gherardi, and M. Esteban Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine J. Virol., January 1, 2000; 74(2): 923 - 933. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. Drexler, E. Antunes, M. Schmitz, T. Wolfel, C. Huber, V. Erfle, P. Rieber, M. Theobald, and G. Sutter Modified Vaccinia Virus Ankara for Delivery of Human Tyrosinase as Melanoma-associated Antigen: Induction of Tyrosinase- and Melanoma-specific Human Leukocyte Antigen A*0201-restricted Cytotoxic T Cells in Vitro and in Vivo Cancer Res., October 1, 1999; 59(19): 4955 - 4963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Geissler, K. Schneider, A. Fleuchaus, C. R. Parrish, G. Sutter, and U. Truyen Feline Calicivirus Capsid Protein Expression and Capsid Assembly in Cultured Feline Cells J. Virol., January 1, 1999; 73(1): 834 - 838. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
